To compare the efficacy of trimetazidine and diltiazem in chronic stable angina

2016-06-23T09-23-22Z
Source: National Journal of Physiology, Pharmacy and Pharmacology
Sharanjit Kaur, Sami Manzoor, Banta Singh, Harinder Jot Singh, Seema Rai, Diksha Kumari.
Background: Trimetazidine, a cytoprotective agent, is better anti-ischemic drug than conventional agents without causing any change in heart rate and blood pressure. Aims and Objectives: To compare the efficacy of trimetazidine with diltiazem in chronic stable angina. Materials and Methods: Thirty diagnosed cases of chronic stable angina were subjected to TMT I with total effort duration and time to precipitate angina being the end point. Patients were given 60 mg of trimetazidine for 8 weeks, in addition to their conventional treatment and subjected to another TMT II with the same end points. After a washout period of 2 weeks, the same patients were put on diltiazem 60 mg TDS for 8 weeks again with another third TMT III to evaluate the results. Results: The mean age of all patients was 57.70 ± 8.44. The mean increase in effort duration between TMT II (7.50 ± 1.52) and I (6.21 ± 1.65 min) was 1.29 min which was statistically significant (P 0.05 not significant). The increase in time to ST-segment depression between TMT I and II was 1.35 min. (P 0.005). Conclusions: The patients with stable angina had a better clinical improvement after treatment with trimetazidine, without any adverse effects.


from Scope via xlomafota13 on Inoreader http://ift.tt/28TpivR
via IFTTT